Ameriprise
DYN icon

Ameriprise’s Dyne Therapeutics DYN Stock Holding History

Ameriprise’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.63M Buy
298,317
+135,345
+83% +$2.52M ﹤0.01% 2359
2026
Q1 		$2.95M Sell
162,972
-34,719
-18% -$599K ﹤0.01% 2762
2025
Q4 		$3.87M Sell
197,691
-224,965
-53% -$4.26M ﹤0.01% 2612
2025
Q3 		$5.35M Buy
422,656
+137,652
+48% +$1.57M ﹤0.01% 2401
2025
Q2 		$2.71M Buy
285,004
+78,039
+38% +$859K ﹤0.01% 2776
2025
Q1 		$2.16M Sell
206,965
-12,670
-6% -$181K ﹤0.01% 2851
2024
Q4 		$5.17M Buy
219,635
+6,735
+3% +$199K ﹤0.01% 2329
2024
Q3 		$7.65M Buy
212,900
+186,872
+718% +$7.44M ﹤0.01% 2042
2024
Q2 		$919K Buy
+26,028
New +$756K ﹤0.01% 3188
2023
Q3 		– Sell
-13,300
Closed -$150K – 3903
2023
Q2 		$150K Sell
13,300
-36,211
-73% -$427K ﹤0.01% 3770
2023
Q1 		$570K Buy
49,511
+26,291
+113% +$341K ﹤0.01% 3381
2022
Q4 		$269K Hold
23,220
– – ﹤0.01% 3621
2022
Q3 		$295K Buy
+23,220
New +$266K ﹤0.01% 3588

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Ameriprise's DYN Position: Q2 2026 in Review

Ameriprise increased its Dyne Therapeutics (DYN) stake by 83% in Q2 2026, buying an estimated $2.52M and bringing the position to 298,317 shares worth $6.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2359.

Ameriprise first reported a position in DYN in Q3 2022 and has held it in 13 quarters since. The position peaked at $7.65M in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Ameriprise held 298,317 shares of Dyne Therapeutics worth $6.63M as of Q2 2026.
  • Ameriprise bought 135,345 Dyne Therapeutics shares in Q2 2026, an estimated $2.52M.
  • Dyne Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2359 holding.
  • Ameriprise first reported a position in Dyne Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • Ameriprise's Dyne Therapeutics position peaked at $7.65M in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.